The growth of biotech startups has expanded the number of companies using animals in early-stage research, often with less developed welfare infrastructure than large pharmaceutical companies.
Biotech startup animal welfare falls into a governance gap. Large pharmaceutical companies have developed welfare infrastructure over decades of regulatory requirement. Small startups conducting early-stage research often lack dedicated welfare officers, established 3Rs programs, and the institutional culture that implements welfare beyond minimum compliance. The pace and financial pressure of startup environments can create implicit pressure against welfare refinements that add time or cost. Industry associations and research funders increasingly recognize this gap and are developing requirements and resources to support startup welfare capacity, recognizing that good welfare also produces better and more reproducible science.